Tumour budding
|
|
0.010 |
GeneticVariation
|
BEFREE |
KRas G12V primary tumors had lower apoptosis (7.0 ± 1.2 vs. 7.4 ± 1.0 per field, P = 0.02), higher tumor budding at the invasion front (1.2 ± 0.2 vs. 0.6 ± 0.1, P = 0.04), and a higher percentage of C-X-C chemokine receptor type 4 (CXCR4)-overexpressing intravasated tumor emboli (49.8 ± 9.4% vs. 12.8 ± 4.4%, P < 0.001) than KRas G13D tumors.
|
25359494 |
2015 |
Thyroid Neoplasm
|
|
0.700 |
CausalMutation
|
CLINVAR |
Beneficial effects of sorafenib on tumor progression, but not on radioiodine uptake, in patients with differentiated thyroid carcinoma.
|
19773371 |
2009 |
Thyroid Neoplasm
|
|
0.700 |
CausalMutation
|
CLINVAR |
Hyperactive Ras in developmental disorders and cancer.
|
17384584 |
2007 |
Thyroid Neoplasm
|
|
0.700 |
CausalMutation
|
CLINVAR |
Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer.
|
23406027 |
2013 |
Thyroid Neoplasm
|
|
0.700 |
CausalMutation
|
CLINVAR |
Phase II trial of sorafenib in metastatic thyroid cancer.
|
19255327 |
2009 |
Thymoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
One thymoma and one thymic carcinoma harbored KRAS mutations (G12A and G12V, respectively), and one thymoma had a G13V HRAS mutation.
|
19861435 |
2009 |
Stomach Carcinoma
|
|
0.700 |
GeneticVariation
|
UNIPROT |
|
|
|
Squamous cell carcinoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
Analysis indicated one SCC patient (2.3%) exhibited a KRAS p.G13D mutation, and one adenocarcinoma patient (2.3%) exhibited a BRAF p.V600E mutation.
|
27573925 |
2016 |
Sezary Syndrome
|
|
0.010 |
GeneticVariation
|
BEFREE |
One mycosis fungoides and one pleomorphic CTCL harbored a KRAS(G13D) mutation; one Sézary syndrome and one CD30(+) CTCL harbored a NRAS(Q61K) amino acid change.
|
21209378 |
2011 |
Secondary Neoplasm
|
|
0.010 |
GeneticVariation
|
BEFREE |
Thus, a mutation frequency of 40% and a cluster of three mutation types (p.G12D, pG12V, and p.G13D) in primaries and metastases can be defined as benchmarks for routine KRAS analyses.
|
19679400 |
2009 |
Secondary malignant neoplasm of colon and/or rectum
|
|
0.090 |
GeneticVariation
|
BEFREE |
In patients with G13D-mutated chemotherapy-refractory mCRC, there was no statistically significant improvement in disease control at 6 months with either cetuximab monotherapy or cetuximab plus irinotecan.
|
27114605 |
2016 |
Secondary malignant neoplasm of colon and/or rectum
|
|
0.090 |
GeneticVariation
|
BEFREE |
Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab.
|
20978259 |
2010 |
Secondary malignant neoplasm of colon and/or rectum
|
|
0.090 |
GeneticVariation
|
BEFREE |
This meta-analysis demonstrates no significant difference between KRAS G13D and other KRAS MT tumours in terms of treatment benefit from anti-EGFR mAbs for mCRC.
|
26812186 |
2016 |
Secondary malignant neoplasm of colon and/or rectum
|
|
0.090 |
GeneticVariation
|
BEFREE |
Patients who had mCRC with the KRAS p.G13D mutation appeared to benefit more from cetuximab than patients who had tumors with KRAS codon 12 mutations.
|
22972628 |
2013 |
Secondary malignant neoplasm of colon and/or rectum
|
|
0.090 |
GeneticVariation
|
BEFREE |
Association of KRAS G13D tumor mutations with outcome in patients with metastatic colorectal cancer treated with first-line chemotherapy with or without cetuximab.
|
22734028 |
2012 |
Secondary malignant neoplasm of colon and/or rectum
|
|
0.090 |
GeneticVariation
|
BEFREE |
Randomized phase II study of cetuximab versus irinotecan and cetuximab in patients with chemo-refractory KRAS codon G13D metastatic colorectal cancer (G13D-study).
|
27878354 |
2017 |
Secondary malignant neoplasm of colon and/or rectum
|
|
0.090 |
GeneticVariation
|
BEFREE |
ICECREAM is a randomised, phase II, open-label, controlled trial comparing the efficacy of cetuximab alone or with irinotecan in patients with "quadruple wild type" or G13D-mutated metastatic colorectal cancer, whose disease has progressed on, or who are intolerant of oxaliplatin- and fluoropyrimidine-based chemotherapy.
|
27246726 |
2016 |
Secondary malignant neoplasm of colon and/or rectum
|
|
0.090 |
GeneticVariation
|
BEFREE |
Influence of KRAS p.G13D mutation in patients with metastatic colorectal cancer treated with cetuximab.
|
22537608 |
2012 |
Secondary malignant neoplasm of colon and/or rectum
|
|
0.090 |
GeneticVariation
|
BEFREE |
This retrospective pooled analysis suggests comparable efficacy of cetuximab-based and bevacizumab-based first-line therapy in patients with p.G13D mutant mCRC.
|
22441566 |
2012 |
Refractory Colorectal Carcinoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
In this analysis, use of cetuximab was associated with longer overall and progression-free survival among patients with chemotherapy-refractory colorectal cancer with p.G13D-mutated tumors than with other KRAS-mutated tumors.
|
20978259 |
2010 |
RAS-ASSOCIATED AUTOIMMUNE LEUKOPROLIFERATIVE DISORDER
|
|
0.700 |
CausalMutation
|
CLINVAR |
|
|
|
ovarian neoplasm
|
|
0.700 |
CausalMutation
|
CLINVAR |
Epidermal growth factor receptor blockers for the treatment of ovarian cancer.
|
21975775 |
2011 |
ovarian neoplasm
|
|
0.700 |
CausalMutation
|
CLINVAR |
KRAS or BRAF mutation status is a useful predictor of sensitivity to MEK inhibition in ovarian cancer.
|
19018267 |
2008 |
Non-Small Cell Lung Carcinoma
|
|
0.700 |
CausalMutation
|
CLINVAR |
Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma.
|
18794081 |
2008 |
Non-Small Cell Lung Carcinoma
|
|
0.700 |
CausalMutation
|
CLINVAR |
Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma.
|
18794081 |
2008 |